Ann: MEETING: PEB: Resolution Passed at Pacific Edge Special Meeting

• Release Date: 26/02/16 14:09
• Summary: MEETING: PEB: Resolution Passed at Pacific Edge Special Meeting
• Price Sensitive: No
• Download Document  5.17KB

					PEB
26/02/2016 14:09
MEETING
PRICE SENSITIVE
REL: 1409 HRS Pacific Edge Limited

MEETING: PEB: Resolution Passed at Pacific Edge Special Meeting

26 February 2016

RESOLUTION PASSED AT PACIFIC EDGE SPECIAL MEETING

Pacific Edge (PEB:NZX) shareholders voted in favour of an increase in the
maximum aggregate amount per annum payable by the company to its directors to
$275,000, at today's special meeting. The increase is to allow for
remuneration of newly appointed, US-based Independent Director, David
Levison. There will be no increase to any other Pacific Edge Director's fees.

Results of the voting

 FOR: 152,360,506 - 84.76%

 AGAINST: 27,394,223 - 15.24%

Pacific Edge has determined that David Levison is an Independent Director, as
defined in Listing Rule 1.6.1.

Progress Update

Pacific Edge Chief Executive, David Darling, provided shareholders with an
update on progress in the year to date. Key highlights include:

o Launch of third product, Cxbladder Monitor, in New Zealand in late 2015, on
time and to specification. This product is now being readied for launch in
the US in 2016
o Achieved targeted sales force size in the US with 18 specialist sales
executives covering 19 targeted major metropolitan regions
o Recruitment for the Kaiser Permanente User Programme is progressing well
and is expected to be completed on time in 2016
o The company is making good progress in its discussions with the Veteran's
Administration and the Centre for Medicare and Medicaid Services and
approvals are expected in the near future
o A new commercial partnership has been announced with specialised
uro-oncology company, Tolmar in Australia, to market and sell Cxbladder
products
o In New Zealand the company continues to work very closely with urologists
and encourage uptake of the Cxbladder technology
o Investigations into the market opportunity in South East Asia continue and
a beachhead is being established in Singapore to provide entry into this
region.

More detail is available in the Special Meeting presentation and address
released to the NZX this morning.

ENDS

For more information contact:
David Darling, Chief Executive Officer, Pacific Edge Ltd, P: +64 (3) 479 5800

OVERVIEW  www.pacificedge.co.nz   www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer
diagnostic company specialising in the discovery and commercialisation of
diagnostic and prognostic tests for better detection and management of
cancer. The company is developing and commercialising its range of Cxbladder
bladder cancer tests globally through its wholly owned central laboratories
in New Zealand and the USA. The company's products have been tested and
validated in international multi-centre clinical studies. Pacific Edge has
two proprietary, novel, accurate, molecular diagnostic products in-market
providing actionable results, and better detection and management of
urothelial cancer. Cxbladder Detect is available through the company's
dedicated CLIA certified laboratories for customers in New Zealand, Australia
and the USA. Cxbladder Triage is available in New Zealand and Australia.
Cxbladder Monitor launched in New Zealand in December 2015 and is anticipated
being available in the US in 2016.

ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional
phenotypic and clinical risk factors to accurately identify patients with
haematuria who have a low probability of bladder cancer and may not require a
more extensive urological evaluation. Cxbladder Triage is a tool for use by
clinicians and physicians in primary evaluation of patients with hematuria
and is intended to reduce the need for an expensive and invasive work-up in
patients who have a low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other
urinary tract cancers from a small volume of a patients' urine. Cxbladder
Detect was launched in 2013 in the USA and is commercially available in New
Zealand, Australia and the USA as a Laboratory Developed Test (LDT) from the
company's CLIA certified laboratories. Cxbladder Detect provides physicians
and clinicians with a quick, cost effective and accurate measure of the
presence of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor  www.cxbladder.com
Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists,
is a proprietary, non-invasive, molecular diagnostic test that combines
genomic biomarkers measured from a small quantity of a patient's urine, with
patient specific clinical factors to better monitor bladder cancer patients
for recurrence. Bladder cancer has a recurrence rate of 50-80% and requires
life-long surveillance. Cxbladder Monitor accurately identifies patients with
a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows
that they have a low probability of recurrent urothelial carcinoma. Cxbladder
Monitor is designed to be used as the preferred adjunct test to cystoscopy in
the management of patients for ongoing evaluation of recurrent bladder
cancer.

Refer to www.cxbladder.com for more information.
End CA:00278427 For:PEB    Type:MEETING    Time:2016-02-26 14:09:13